Notice for Dupilumab (rch) (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
Dupilumab (rch)
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Dupilumab is indicated as an add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) associated with type 2 inflammation.
Therapeutic area
Respiratory